Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda, Eisai Look Abroad To Expand Drug Sales With Cancer, Diabetes Products

This article was originally published in PharmAsia News

Executive Summary

Japanese drug makers Takeda Pharmaceutical and Eisai plan to expand beyond their home country to take advantage of overseas markets for their drugs. The desire is driven by patents expiring in the next two years on some of the best-selling products. Takeda is about to market a new prostate cancer treatment (leuprorelin) in France, and Eisai has applied in 10 countries in Southeast Asia to market its Glufast (mitiglinide) diabetes drug. Mitsubishi Tanabe Pharma and Shionogi also have plans to market drugs abroad. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts